CLINICAL TRIALS PROFILE FOR CYTALUX
✉ Email this page to a colleague
All Clinical Trials for CYTALUX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT06235125 ↗ | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children | RECRUITING | On Target Laboratories, LLC | PHASE1 | 2024-04-08 | Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach. |
| NCT06235125 ↗ | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children | RECRUITING | Ann & Robert H Lurie Children's Hospital of Chicago | PHASE1 | 2024-04-08 | Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach. |
| NCT06434909 ↗ | CYTALUX™for the Intraoperative Imaging of Prostate Cancer | RECRUITING | On Target Laboratories, LLC | PHASE1 | 2024-09-19 | This study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in ovarian cancer (2021) and lung cancer surgery (2022.) |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CYTALUX
Condition Name
Clinical Trial Locations for CYTALUX
Trials by Country
Clinical Trial Progress for CYTALUX
Clinical Trial Phase
Clinical Trial Sponsors for CYTALUX
Sponsor Name
